Physician profile
Ryan A Kalinsky
NPI 1477727139
$5,992.52
in general payments reported to CMS, 2019-2025
55 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $194 · 2021: $185 · 2022: $608 · 2023: $1,614 · 2024: $1,633 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,874.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $806.36 | 2020-2025 | |
| Gilead Sciences, INC. | $526.45 | 2021-2025 | Trodelvy |
| Pfizer INC. | $421.55 | 2022-2025 | |
| Janssen Biotech, INC. | $298.81 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Daiichi Sankyo INC. | $248.33 | 2020-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $217.20 | 2020-2025 | Opdivo, Eliquis, Augtyro |
| Genzyme Corporation | $211.73 | 2020-2024 | |
| Amgen INC. | $209.85 | 2019-2025 | Prolia, Evenity, Blincyto |
| Merck Sharp & Dohme LLC | $203.19 | 2022-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $163.59 | 2021-2025 | Ojjaara, Shingrix |
| Celgene Corporation | $153.73 | 2021-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $133.42 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Jazz Pharmaceuticals INC. | $124.69 | 2021-2025 | |
| Genentech USA, INC. | $118.95 | 2019-2025 | Phesgo, Venclexta, Itovebi |
| Abbvie INC. | $108.93 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $105.99 | 2020-2024 | |
| Array Biopharma INC | $98.57 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $98.57 | 2023-2025 | Vyloy, Xospata, Padcev |
| Sumitomo Pharma America, INC. | $96.29 | 2023-2025 | Orgovyx |
| Emd Serono, INC. | $94.69 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $89.04 | 2023-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $88.56 | 2022-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $88.27 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beigene USA, INC. | $82.69 | 2023-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $82.22 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.17 | 2024-2025 | Fruzaqla, Alunbrig |
| Adc Therapeutics America, INC. | $62.71 | 2025 | |
| Deciphera Pharmaceuticals INC. | $61.46 | 2023-2025 | Qinlock, Romvimza |
| Seagen INC. | $59.03 | 2023 | Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.75 | 2025 | |
| Fresenius Kabi USA, LLC | $52.20 | 2025 | Stimufend |
| Integra Lifesciences Corporation | $50.34 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Alnylam Pharmaceuticals INC. | $46.13 | 2024 | Givlaari |
| Incyte Corporation | $41.98 | 2023-2024 | Pemazyre, Monjuvi, Jakafi |
| Puma Biotechnology, INC. | $41.31 | 2020-2023 | |
| Mirati Therapeutics, INC. | $40.71 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $40.44 | 2023-2024 | Monoferric |
| Springworks Therapeutics, INC. | $40.40 | 2025 | Ogsiveo, Gomekli |
| Medtronic, INC. | $40.07 | 2023 | Osteocool Rf Ablation System |
| G1 Therapeutics, INC. | $38.49 | 2022-2023 | Cosela |
| Tersera Therapeutics LLC | $37.38 | 2025 | Xermelo |
| Shield Therapeutics INC | $35.74 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $31.94 | 2025 | Provenge |
| Cumberland Pharmaceuticals, INC. | $31.74 | 2023-2025 | Sancuso |
| Alexion Pharmaceuticals, INC. | $30.45 | 2021-2025 | Ultomiris |
| Blue Earth Diagnostics | $29.73 | 2023 | |
| Geron Corporation | $28.01 | 2025 | Rytelo |
| Taiho Oncology, INC. | $27.74 | 2025 | |
| Tempus Ai, INC | $27.05 | 2024 | Xt Cdx |
| Genmab U.S., INC. | $25.04 | 2024 | Epkinly |
| Sobi, INC | $19.23 | 2023 | |
| Agios Pharmaceuticals, INC. | $17.62 | 2024 | |
| Dova Pharmaceuticals | $14.90 | 2021 | |
| Morphosys, US INC. | $14.58 | 2023 | Monjuvi |
| Kite Pharma, INC. | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kalinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.